Erkurt M.A.Berber I.Tekgündüz E.Dogu M.H.Korkmaz S.Demir C.Yilmaz M.Akay O.M.Pala C.Bilen Y.Kaya E.Sari I.Sencan M.Kuku I.Altuntaş F.Dal M.S.Aydogdu I.2024-07-222024-07-22201614730502http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15922We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd.EnglishAgedAged, 80 and overCentral Nervous System NeoplasmsDemographyHumansLymphomaMiddle AgedPractice Patterns, Physicians'RecurrenceRetrospective StudiesStem Cell TransplantationTransplantation, AutologousYoung AdultbusulfancyclophosphamidecytarabineetoposidemelphalanthiotepaadultagedArticleautologous stem cell transplantationcancer chemotherapycancer prognosiscancer radiotherapyfemalefollow upgeneral practicehumanmajor clinical studymalemedical record reviewmortalitymulticenter studyoverall survivalprimary central nervous system lymphomarecurrence free survivalrelapseremissionretrospective studyvery elderlyautotransplantationCentral Nervous System Neoplasmsclinical practiceclinical trialdemographylymphomamiddle agedrecurrent diseasestem cell transplantationyoung adultArticle10.1016/j.transci.2016.01.018